News & Updates

Show Multimedia Only
Ixazomib regimens disappoint in older patients with multiple myeloma

Ixazomib regimens disappoint in older patients with multiple myeloma

06 Jan 2022

Induction with ixazomib-based regimens appear to be insufficient for older patients newly diagnosed multiple myeloma who are ineligible for transplantation, achieving an unsatisfactory progression-free survival (PFS) rate, reports a recent study.

06 Jan 2022
Entinostat-exemestane combo yields survival benefit for HR+ advanced BC

Entinostat-exemestane combo yields survival benefit for HR+ advanced BC

04 Jan 2022 byAudrey Abella

In women with hormone-receptor positive advanced breast cancer (HR+ aBC), the addition of the class I selective histone deacetylase (HDAC) inhibitor entinostat to exemestane appeared to be better than treatment with exemestane alone in terms of survival benefit, according to a phase III trial from China.

04 Jan 2022
Early mortality high among multiple myeloma patients

Early mortality high among multiple myeloma patients

30 Dec 2021

Though decreasing over time, early mortality remains high in patients with multiple myeloma (MM), a recent study has found. Important risk factors include older age, a more aggressive disease, and a patient’s poor physical condition.

30 Dec 2021